First patients sought for groundbreaking cancer drug trial
NCT ID NCT06427941
Summary
This is a first-in-human study to test the safety and initial effectiveness of a new drug called BGB-B2033. It will be given alone or in combination with other cancer drugs to people with specific advanced or metastatic solid tumors, including certain liver, lung, stomach, and germ cell cancers. The main goals are to find a safe dose and see how the body handles the drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anhui Provincial Hospital
RECRUITINGHefei, Anhui, 230000, China
-
Auckland City Hospital
RECRUITINGAuckland, 1023, New Zealand
-
Cha Bundang Medical Center, Cha University
RECRUITINGBundangGu SeongnamSi, Gyeonggi-do, 13496, South Korea
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, Heilongjiang, 150000, China
-
Hospital Oncologico
RECRUITINGRio Piedras, 00935, Puerto Rico
-
Hunan Cancer Hospital
RECRUITINGChangsha, Hunan, 410013, China
-
Memorial Sloan Kettering Cancer Center Mskcc
RECRUITINGNew York, New York, 10065-6800, United States
-
Mengchao Hepatobiliary Hospital of Fujian Medical University
RECRUITINGFuzhou, Fujian, 350025, China
-
Nanfang Hospital of Southern Medical University
RECRUITINGGuangzhou, Guangdong, 510515, China
-
Samsung Medical Center
RECRUITINGGangnamGu, Seoul Teugbyeolsi, 06351, South Korea
-
Scri Oncology Partners
RECRUITINGNashville, Tennessee, 37203-1503, United States
-
Seoul National University Bundang Hospital
RECRUITINGSeongnam-si, Gyeonggi-do, 13620, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, Seoul Teugbyeolsi, 03080, South Korea
-
Severance Hospital Yonsei University Health System
RECRUITINGSeodaemunGu, Seoul Teugbyeolsi, 03722, South Korea
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310003, China
-
The Second Affiliated Hospital of Nanchang University
RECRUITINGNanchang, Jiangxi, 330006, China
-
The Second Affiliated Hospital of Nanchang Universityhongjiaozhou Branch
RECRUITINGNanchang, Jiangxi, 330038, China
-
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430022, China
-
Upmc Hillman Cancer Center(Univ of Pittsburgh)
RECRUITINGPittsburgh, Pennsylvania, 15232-1309, United States
Conditions
Explore the condition pages connected to this study.